About
Research
Patient Care
Education & Training
Community
Jun 17, 2024 | UCI Public Health
UC Irvine joins a national network of partners to address cancer, the leading cause of death, among Asian Americans
Asian Americans have become the first racial/ethnic group for whom cancer is the leading cause of death. Yet, Asian Americans are often underrepresented in clinical trials and cancer research. To address this, the NCI has awarded $12.45 million to create a national cohort called ASPIRE.
UCI CFCCC Bulletin
June 12, 2024
Jun 10, 2024
‘Cutting the cable’ between CD8+ T and T regulatory cells enhances checkpoint immunotherapy
“Our latest research reveals that CD8+ T cells, activated by PD-1 blockade to target melanoma, also interact with T regulatory cells, which subsequently dampen the immune response against the tumor,” said corresponding author Francesco Marangoni, UC Irvine assistant professor of physiology & biophysics.
Jun 04, 2024
UCI Health cancer specialists share research at national forum
UCI Health cancer clinicians and scientists presented key findings and insights that will help advance cancer research and care at the 2024 annual meeting of the American Society of Clinical Oncology (ASCO), one of the world’s largest scientific gatherings in the field.
May 31, 2024
UCI Anti-Cancer Challenge awards $1 million for promising cancer research
The UCI Anti-Cancer Challenge has awarded $1 million raised in 2023 to fund a new round of transformative research projects at the UCI Health Chao Family Comprehensive Cancer Center and its pediatric cancer affiliate, Children’s Hospital of Orange County (CHOC).
A literal gut check
A healthy microbiome in your digestive tract can help stave off heart disease, cancer and other ailments, says Katrine Whiteson, a Chancellor’s Fellow and associate professor of molecular biology and biochemistry at UC Irvine.
May 29, 2024
May 28, 2024
Time Is on Cancer Immunotherapy’s Side
A new study led by a multidisciplinary research team at the University of California (UC), Irvine, demonstrates that the circadian clock can be leveraged to enhance the efficacy of checkpoint inhibitor cancer therapy.
UC Irvine study reveals circadian clock can be leveraged to enhance cancer immunotherapy
UCI researchers have found that the circadian clock can enhance the effectiveness of checkpoint inhibitor cancer therapy by optimizing immune functions and helping T cells target tumors.
May 15, 2024